rotaviru
infect
major
caus
sever
dehydr
diarrhea
infant
younger
old
particular
case
immunocompromis
patient
irrespect
age
patient
although
vaccin
develop
antivir
therapi
import
complement
substitut
lack
specif
approv
treatment
urgent
facilit
cascad
understand
infect
biolog
identif
druggabl
target
final
develop
effect
antivir
therapi
signal
pathway
play
vital
role
regul
infect
cours
mani
virus
studi
dissect
effect
signal
pathway
rotaviru
infect
use
convent
cell
cultur
model
model
human
primari
intestin
organoid
found
signal
essenti
sustain
rotaviru
infect
thu
block
key
element
pathway
includ
mtor
result
potent
antirotaviru
activ
importantli
clinic
use
mtor
inhibitor
rapamycin
potent
inhibit
experiment
patientderiv
rotaviru
strain
effect
involv
mediat
induct
autophagi
turn
exert
antirotaviru
effect
result
reveal
new
insight
rotavirushost
interact
provid
new
avenu
antivir
drug
develop
rotaviru
member
reovirida
famili
lead
caus
sever
dehydr
diarrhea
mainli
attack
children
younger
old
result
approxim
million
diarrheal
episod
infant
death
annual
besid
children
accumul
evid
indic
rotaviru
could
also
caus
chronic
infect
organ
transplant
patient
irrespect
age
patient
although
safe
licens
vaccin
name
rotateq
merck
co
pa
usa
rotarix
gsk
biolog
rixensart
belgium
avail
implement
vaccin
mani
develop
countri
remain
challeng
due
high
cost
logist
issu
sinc
approv
medic
avail
develop
effect
antivir
therapi
indispens
combat
pathogen
numer
signal
pathway
play
import
role
regul
viru
infect
either
support
defend
infect
viru
phosphatidylinositol
protein
kinas
b
akt
mammalian
target
rapamycin
mtor
axi
take
vital
part
regul
variou
cellular
function
biolog
process
includ
protein
synthesi
cell
cycl
progress
cell
surviv
apoptosi
angiogenesi
drug
resist
signal
serv
key
node
capabl
monitor
panel
biolog
process
via
phosphoryl
transfer
could
activ
mani
type
cellular
stimuli
subsequ
phosphoryl
inositol
recruit
akt
plasma
membran
bind
ntermin
pleckstrin
homolog
ph
domain
akt
get
activ
via
phosphoryl
serinethreonin
kinas
phosphoryl
akt
abl
stimul
mtor
belong
member
serinethreonin
phosphatidyl
inositol
kinaserel
kinas
famili
pikk
mtor
evolutionarili
conserv
serin
threonin
kinas
play
indispens
role
regul
mrna
translat
autophagi
machineri
cell
prolifer
furthermor
mtor
directli
activ
varieti
cellular
effector
kinas
eukaryot
translat
initi
factor
protein
control
cell
growth
integr
nutrit
inform
receptor
tyrosin
kinas
signal
instanc
mtor
control
cappeddepend
translat
cell
virus
via
induc
phosphoryl
promot
format
function
eukaryot
initi
factor
complex
complex
compris
subunit
includ
rna
helicas
capbind
protein
scaffold
protein
share
canon
motif
sequenc
denot
tyr
x
denot
amino
acid
l
denot
leu
f
denot
hydrophob
residu
contain
noncanon
connect
linker
residu
motif
conserv
requir
bind
autophagi
machineri
anoth
import
downstream
element
mtor
signal
cellular
nonspecif
bulk
degrad
process
involv
remov
damag
macromolecul
organel
defend
nutrient
environment
stress
also
involv
regul
viru
infect
pathway
potenti
antivir
target
involv
infect
broad
spectrum
virus
includ
lymphocyt
choriomening
viru
lcmv
middl
east
respiratori
syndrom
coronaviru
merscov
hiv
human
cytomegaloviru
studi
comprehens
studi
role
signal
rotaviru
infect
explor
avenu
therapeut
target
besid
convent
dimens
cultur
base
immort
cell
also
use
dimens
cultur
primari
human
intestin
organoid
model
rotaviru
infect
organoid
recapitul
aspect
vivo
tissu
architectur
intestin
epithelium
found
pathway
crucial
sustain
rotaviru
infect
via
downstream
effector
induct
autophagi
importantli
target
pathway
pharmacolog
inhibitorsfda
approv
drug
potent
inhibit
rotaviru
infect
provid
novel
therapeut
approach
combat
viru
sinc
serv
key
node
pathway
effect
rotaviru
test
potent
inhibitor
human
cell
treatment
mm
potent
inhibit
correspond
total
protein
control
fig
figur
importantli
treatment
mm
h
result
n
p
n
p
reduct
viral
rna
respect
fig
could
also
significantli
suppress
rotaviru
rna
secret
figur
inhibitori
effect
compound
verifi
tcid
method
demonstr
could
remark
inhibit
product
infecti
viral
particl
fig
western
blot
assay
confirm
treatment
mm
could
vigor
inhibit
rotaviru
protein
synthesi
cell
fig
effect
drug
also
valid
human
primari
intestin
organoid
immunofluoresc
stain
show
potent
inhibit
treatment
mm
fig
support
human
intestin
organoid
also
signal
profici
model
consist
inhibit
rotaviru
infect
organoid
model
instanc
mm
result
n
p
reduct
viral
rna
human
intestin
organoid
fig
thu
block
potent
inhibit
rotaviru
infect
cell
human
intestin
organoid
mtor
sustain
rotaviru
infect
mtor
inhibitor
rapamycin
inhibit
infect
mtor
central
element
signal
pathway
thu
investig
effect
rotaviru
infect
address
cell
transduc
integr
lentivir
vector
express
shrna
silenc
mtor
one
clone
show
potent
knockdown
base
western
blot
result
fig
also
confirm
qrtpcr
fig
cell
mtor
knockdown
scrambl
shrna
control
inocul
rotaviru
viral
genom
rna
quantifi
qrtpcr
h
post
inocul
silenc
mtor
led
signific
reduct
rotaviru
rna
fig
suggest
support
role
mtor
rotaviru
infect
rapamycin
clinic
use
mtor
inhibitor
approv
fda
treatprev
transplant
allograft
reject
phosphoryl
mtor
correspond
total
protein
control
inhibit
treatment
nm
rapamycin
h
cell
fig
figur
except
phosphoryl
akt
inhibit
rapamycin
report
trigger
neg
feedback
loop
activ
akt
signal
might
reason
rapamycin
minor
inhibitori
effect
phosphoryl
akt
furthermor
treatment
nm
rapamycin
significantli
inhibit
viral
genom
rna
n
p
n
p
cell
respect
fig
rotaviru
rna
secret
figur
infecti
viru
product
fig
also
significantli
inhibit
treatment
rapamycin
consist
western
blot
assay
indic
rotaviru
protein
synthesi
potent
inhibit
rapamycin
treatment
fig
contrast
rapamycin
lost
antirotaviru
activ
mtor
silenc
cell
fig
support
specif
inhibit
biolog
target
exert
antivir
action
verifi
antirotaviru
effect
rapamycin
human
intestin
organoid
infect
rotaviru
treat
nm
rapamycin
h
led
vigor
inhibit
fig
importantli
nm
rapamycin
result
signific
reduct
n
p
viral
rna
replic
fig
valid
patientderiv
strain
inocul
cell
human
intestin
organoid
stool
sampl
rotavirusinfect
patient
tabl
treatment
nm
rapamycin
inhibit
patientderiv
isol
cell
fig
human
intestin
organoid
fig
result
demonstr
effici
infect
rotaviru
requir
mtor
infect
effect
inhibit
rapamycin
pharmacolog
dual
inhibitor
mtor
western
blot
confirm
compound
could
potent
inhibit
phosphoryl
mtor
akt
correspond
total
protein
control
cell
fig
figur
importantli
dosedepend
inhibit
viral
rna
fig
rna
secret
cell
figur
use
tcid
method
demonstr
remark
inhibit
product
infecti
viral
particl
fig
also
capabl
inhibit
synthesi
rotaviru
protein
fig
effect
also
confirm
human
intestin
organoid
inhibit
phosphoryl
fig
rotaviru
infect
fig
although
rotaviru
infect
directli
affect
express
level
key
compon
pathway
figur
pathway
intrins
sustain
rotaviru
infect
one
import
downstream
element
signal
first
studi
potenti
involv
lentivir
rnai
mediat
lossoffunct
assay
fig
figur
cell
best
knockdown
result
n
p
reduct
rotaviru
viral
rna
h
postinocul
fig
consist
antirotaviru
effect
rapamycin
abolish
knockdown
cell
confirm
qrtpcr
assay
fig
western
blot
assay
fig
verifi
obtain
knockout
mous
embryon
fibroblast
mef
bona
fide
knockout
wildtyp
plasmid
antivir
effect
abolish
ko
mef
transfect
plasmid
mutat
phosphoryl
site
fig
note
inhibitor
affect
rotaviru
infect
figur
collect
data
suggest
downstream
effector
signal
sustain
rotaviru
infect
previou
studi
report
rapamycin
may
affect
type
ifn
signal
particular
downstream
antivir
protein
includ
interferon
regulatori
factor
furthermor
previous
report
antirotaviru
effect
ifna
thu
investig
whether
antivir
protein
may
play
role
set
found
rapamycin
treatment
affect
protein
express
cell
mef
figur
b
although
defici
appear
slightli
increas
protein
synthesi
figur
thu
result
indic
antivir
protein
like
essenti
antirotaviru
action
signal
therefor
redirect
attent
autophagi
cellular
metabol
process
function
orderli
degrad
recycl
cellular
compon
implic
regul
mani
type
viru
infect
mtor
main
inhibitor
autophagi
rapamycin
specif
inhibitor
mtor
potent
induc
autophagi
format
first
confirm
starvat
ebss
medium
contain
pepstatin
solut
posit
control
stimul
autophagi
process
cell
fig
consist
ratio
hallmark
autophagi
induct
upregul
rapamycin
treatment
fig
figur
treatment
starvat
fig
figur
similar
rapamycin
treatment
fig
starvat
also
significantli
inhibit
rotaviru
mrna
fig
viral
protein
synthesi
fig
figur
interestingli
induct
autophagi
rapamycin
starvat
confirm
via
autophagi
equal
increas
rapamycin
treatment
phosphoryl
mutant
fig
consist
upregul
ratio
rapamycin
starvat
block
knockout
mef
cell
fig
h
demonstr
role
autophagi
rotaviru
infect
appli
rnai
knockdown
key
compon
autophagi
machineri
aim
gene
associ
autophagosom
membran
silenc
integr
lentivir
rnai
vector
five
show
potent
knockdown
fig
signific
increas
rotaviru
genom
rna
found
knockdown
cell
line
quantifi
qrtpcr
fig
confirm
viral
protein
synthesi
increas
knockdown
cell
line
fig
play
import
role
local
autophag
protein
preautophagosom
structur
similarli
knockdown
also
favor
rotaviru
infect
fig
e
f
note
optim
knockdown
clone
found
increas
rotaviru
genom
rna
n
p
n
p
n
p
fold
respect
fig
viral
protein
synthesi
confirm
increas
knockdown
cell
fig
thu
conclud
mediat
rapamycininduc
autophagi
machineri
inhibit
rotaviru
infect
mani
virus
interfer
use
pathway
regul
infect
vesicular
stomat
viru
vsv
infect
replic
report
lead
dephosphoryl
inactiv
akt
contrast
influenza
viru
replic
activ
akt
phosphoryl
viral
protein
directli
bind
regulatori
subunit
allow
catalyt
domain
phosphoryl
akt
recent
structur
studi
provid
insight
mechan
activ
holoenzym
white
spot
syndrom
viru
wssv
stimul
phosphoryl
downstream
element
pathway
semliki
forest
viru
sfv
human
papillomaviru
type
also
report
phosphoryl
mtor
target
kinas
fact
pathway
serv
proor
antivir
doubleedg
sword
depend
type
virus
pathway
demonstr
exert
inhibitori
effect
hepat
e
viru
hev
replic
via
contrast
also
involv
promot
infect
broadspectrum
virus
thu
block
inhibitor
could
vigor
inhibit
infect
numer
virus
includ
lcmv
coxsackieviru
overexpress
akt
stimul
mrna
express
coxsackieviru
rotaviru
infect
report
activ
phosphoryl
piglet
howev
found
evid
rotaviru
infect
induc
phosphoryl
akt
system
cell
human
origin
underli
discrep
might
deriv
differ
speci
distinct
physiolog
situat
sinc
anim
model
case
limit
relev
human
physiolog
howev
pathway
essenti
sustain
rotaviru
infect
inhibit
signal
result
potent
antirotaviru
activ
fig
pathway
function
phosphoryl
downstream
effector
includ
ribosom
protein
kinas
upregul
capdepend
mrna
translat
merkel
cell
polyomaviru
mcv
stir
phosphoryl
subsequ
disassoci
form
complex
induc
mrna
translat
rift
valley
fever
viru
rvfv
induc
decay
top
mrna
via
restrict
viru
replic
demonstr
antirotaviru
effect
inhibit
pathway
predominantli
via
report
mediat
inhibitori
effect
mtor
autophagi
format
studi
confirm
autophagi
induc
inhibit
mtor
treatment
rapamycin
system
process
mediat
process
autophagi
induct
implic
regul
mani
type
viru
infect
variou
mechanismofact
function
demonstr
autophagi
machineri
exert
antivir
effect
rotaviru
fig
e
virus
includ
human
cytomegaloviru
hepat
b
virusx
hbx
chikungunya
viru
report
lure
autophagi
machineri
host
rotaviru
also
report
induc
autophagi
piglet
intestin
howev
observ
chang
ratio
upon
rotaviru
infect
key
autophagi
relat
gene
well
studi
regul
viru
infect
differ
modelofact
sindbi
viru
infect
beclin
express
upregul
may
result
xenophagi
select
autophagi
sindbi
viru
defend
infect
sever
autophagi
relat
gene
promot
innat
adapt
immun
respons
combat
viral
infect
demonstr
silenc
led
potent
increas
rotaviru
infect
fig
clinic
organ
transplant
patient
irrespect
age
sensit
rotaviru
infect
longterm
use
immunosuppress
import
risk
factor
caus
persist
infect
patient
rapamycin
potent
mtor
inhibitor
use
immunosuppress
transplant
patient
decad
well
document
differ
type
immunosuppress
may
differenti
affect
viru
infect
antivir
effect
rapamycin
demonstr
model
herp
simplex
viru
coxsackieviru
infect
data
demonstr
potent
antirotaviru
effect
rapamycin
favor
clinic
applic
immunosuppress
rotavirusinfect
organ
recipi
summari
fig
dissect
effect
signal
rotaviru
infect
demonstr
block
pathway
potent
inhibit
rotaviru
replic
importantli
mtor
inhibitor
rapamycin
induc
autophagi
machineri
inhibit
rotaviru
infect
via
thu
studi
reveal
new
insight
rotavirushost
interact
provid
new
avenu
antivir
drug
develop
furthermor
provid
import
refer
transplant
clinician
design
optim
immunosuppress
protocol
rotaviru
infect
organ
transplant
patient
stock
inhibitor
sigmaaldrich
dual
inhibitor
mtor
selleck
chemic
rapamycin
mtor
inhibitor
merk
schipholrijk
netherland
inhibitor
selleck
chemic
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
st
loui
mo
reagent
store
ml
aliquot
frozen
c
reagent
includ
earl
balanc
salt
solut
ebss
lonza
santa
cruz
biotech
santa
cruz
ca
pepstatin
santa
cruz
biotech
santa
cruz
ca
also
use
simian
rotaviru
use
prepar
describ
previous
patientderiv
rotaviru
isol
isol
stool
sampl
rotavirusinfect
patient
diarrhea
period
describ
previous
cell
human
primari
intestin
organoid
cultur
caucasian
colon
adenocarcinoma
cell
heterogen
human
epitheli
colorect
adenocarcinoma
cell
repres
numer
characterist
enterocyt
commonli
use
vitro
model
rotaviru
infect
cell
maintain
cultur
flask
dulbecco
modifi
eagl
medium
dmem
invitrogengibco
breda
netherland
describ
previous
immort
mous
embryon
fibroblast
mef
deriv
wildtyp
cc
knockout
mice
gift
en
fish
laboratori
cultur
dmem
invitrogengibco
breda
netherland
contain
volvol
fetal
calf
serum
fc
hyclon
lonan
utah
iuml
penicillin
mgml
streptomycin
mm
lglutamin
invitrogengibco
cultur
human
intestin
organoid
perform
describ
previous
briefli
intestin
tissu
vigor
shaken
mm
edta
min
c
follow
remov
edta
solut
subsequ
loosen
crypt
collect
pipet
solut
ml
pipett
time
crypt
suspens
transfer
ml
centrifug
tube
greiner
bioon
netherland
biopsi
reus
repeat
collect
crypt
time
crypt
suspens
pool
centrifug
g
min
pellet
crypt
resuspend
ml
complet
medium
growth
factor
cmgf
advanc
supplement
volvol
glutamax
tm
supplement
gibco
grand
island
usa
mm
hepe
collect
centrifug
g
min
c
crypt
final
suspend
matrigel
corn
bedford
usa
place
center
well
plate
ml
per
well
matrigel
solidifi
min
c
organoid
cultur
cultur
medium
c
co
cultur
medium
refresh
everi
day
organoid
passag
everi
reed
muench
method
appli
determin
infecti
viru
titrat
standard
tcid
protocol
mean
cell
protocol
inocul
cell
patientderiv
rotaviru
describ
previous
briefli
cell
monolay
cell
incub
rotaviru
c
co
min
infect
follow
remov
free
viru
particl
subsequ
cell
ad
cultur
medium
fc
free
contain
mgml
trypsin
indic
drug
follow
incub
c
humidifi
co
incub
organoid
inocul
activ
viru
genom
copi
min
c
co
follow
remov
free
viral
particl
organoid
aliquot
well
plate
coat
volvol
collagen
r
solut
serva
heidelberg
germani
cultur
medium
contain
drug
interest
ad
subsequ
plate
contain
organoid
spin
g
minut
promot
adher
bottom
well
follow
maintain
c
co
prepar
patientderiv
rotaviru
perform
describ
earlier
protocol
viral
inocul
treatment
drug
similar
rotaviru
h
postinfect
use
determin
viral
replic
level
sinc
optim
time
point
viral
replic
without
lysi
cell
total
rna
extract
use
nucleospin
rna
kit
machereynagel
uren
germani
quantifi
nanodrop
wilmington
de
usa
ng
rna
use
templat
cdna
prepar
revers
transcript
system
takara
takara
bio
inc
quantit
realtim
pcr
qrtpcr
reaction
perform
sybr
green
appli
biosystem
austin
usa
accord
manufactur
instruct
qrtpcr
perform
cycler
pcr
machin
biorad
level
glyceraldehyd
dehydrogenas
gapdh
mrna
use
endogen
refer
normal
quantiti
target
mrna
use
formula
ddct
dct
sampl
dct
control
primer
sequenc
indic
tabl
lentivir
plko
knockdown
vector
sigmaaldrich
target
mtor
nontarget
control
lentiviru
obtain
erasmu
biomic
center
produc
human
embryon
kidney
celllin
cell
cell
transduc
lentivir
vector
gener
stabl
gene
knockdown
cell
transduc
cell
subsequ
select
mgml
puromycin
sigma
pilot
studi
shrna
vector
exert
optim
gene
knockdown
select
knockdown
control
cell
incub
rotaviru
describ
forego
plasmid
includ
transfect
knockout
mef
cell
seed
plate
till
confluenc
follow
ad
ml
optimem
reduc
serum
medium
thermo
fisher
scientif
mg
plasmid
ml
fugen
transfect
reagent
roch
appli
scienc
inc
transfect
cell
incub
complet
medium
h
follow
refresh
nm
rapamycin
control
medium
h
cell
analyz
western
blot
treatment
experi
execut
triplic
treatment
wash
pb
cell
plate
lyse
ml
laemmli
buffer
volvol
glycerol
wtvol
sd
mm
trishcl
ph
contain
mm
dtt
boil
min
c
cell
lysat
subject
sdspage
protein
transfer
polyvinyliden
difluorid
pvdf
membran
immobilonfl
subsequ
membran
block
ml
block
buffer
ml
pb
contain
tween
pbst
hour
room
temperatur
follow
incub
pmtor
rabbit
cell
signal
tmtor
rabbit
cell
signal
pakt
rabbit
cell
signal
takt
rabbit
cell
signal
rabbit
cell
signal
rabbit
cell
signal
rabbit
cell
signal
rabbit
cell
signal
rabbit
cell
signal
rotaviru
mous
monoclon
provid
professor
harri
greenberg
stanford
univers
school
medicin
usa
overnight
ml
block
bufferpbst
cocktail
c
wash
pbst
immunoreact
band
detect
western
blot
analysi
detect
bactin
serv
load
control
mous
monoclon
santa
cruz
organoid
harvest
matrigel
use
cold
pb
follow
fix
paraformaldehyd
pb
c
min
fix
organoid
ad
appropri
well
cytospin
ii
cytocentrifug
shandon
scientifi
ltd
runcorn
england
spin
rpm
min
slide
contain
organoid
rins
pbsbath
min
follow
treatment
volvol
min
slide
rins
pbsbath
min
follow
incub
milktweenglycin
medium
tween
skim
milk
glycin
block
background
stain
min
slide
incub
humid
chamber
antibodi
rabbit
cell
signal
dilut
milktweenglycin
medium
c
overnight
slide
wash
min
pbsbath
h
incub
dilut
antirabbit
igg
h
c
l
f
ab
fragment
alexa
fluor
conjug
secondari
antibodi
nuclei
stain
dapi
invitrogen
imag
detect
use
confoc
electroscop
cell
cultur
cover
slide
bottom
well
cultur
medium
transduc
lentivir
particl
carri
construct
driven
elong
promot
millipor
lentibrit
multipl
infect
moi
h
medium
chang
pharmacolog
treatment
indic
time
period
live
imag
obtain
use
confoc
electroscop
effect
chemic
reagent
cell
viabil
determin
mtt
assay
figur
briefli
cell
seed
cell
per
well
plate
viabl
cell
detect
indic
time
point
ad
ml
mgml
mtt
per
well
h
incub
c
replac
medium
ml
dmso
sigma
absorb
nm
analyz
intestin
organoid
embed
matrigel
cultur
well
organoid
cultur
medium
contain
relev
chemic
reagent
effect
relat
chemic
reagent
intestin
organoid
viabil
determin
morpholog
organoid
observ
light
microscop
figur
numer
result
express
mean
sem
statist
comparison
analyz
mannwhitney
test
data
without
normal
distribut
test
data
normal
distribut
pvalu
less
consid
statist
signific
analysi
perform
use
graphpad
prism
version
graphpad
softwar
inc
la
jolla
ca
potenti
conflict
interest
disclos
yy
wd
xz
l
x
ww
wc
sc
js
perform
experi
xc
sx
contribut
scientif
discuss
facil
manuscript
edit
yy
mp
qp
conceiv
project
wrote
manuscript
